UK markets closed

Cosmo Pharmaceuticals N.V. (0RGI.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
69.90+1.70 (+2.49%)
At close: 04:01PM BST

Cosmo Pharmaceuticals N.V.

Riverside II
Sir John Rogerson’s Quay
Dublin 2
Ireland
353 1 817 0370
https://www.cosmopharma.com

Sector(s)
Industry
Full-time employees325

Key executives

NameTitlePayExercisedYear born
Mr. Alessandro E. Della Cha LL.MExecutive Chairman588kN/A1963
Mr. Niall DonnellyExecutive Director & CFON/AN/A1972
Mr. Giovanni Di NapoliChief Executive Officer & DirectorN/AN/A1974
Mr. Mauro Severino AjaniFounder & Non-Executive Director387.6kN/A1955
Mr. Marco LecchiChief Operating OfficerN/AN/A1964
Mr. Davide MalavasiQualified Person & Technical DirectorN/AN/A1973
Mr. Luigi LongoChief Scientific OfficerN/AN/A1979
Ms. Hazel WinchesterHead of Investor RelationsN/AN/A1971
Mr. Biagio ViganoChief People OfficerN/AN/A1974
Mr. Roberto VillaChief Manufacturing OfficerN/AN/A1943
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.

Description

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, a submucosal injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin SV MMX – IBS-D, a formulation that is in Phase III clinical trial to treat colonic infections and irritable bowel syndrome with diarrhoea; CB-03-10, an oral androgen receptor antagonist, which is in Phase I clinical trial for treatment solid tumors; CB-01-33 that is in preclinical studies for the treatment of bile acid diarrhea; and CB-01-35, an enema solution, which is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, RedHill Biopharma Ltd., Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Corporate governance

Cosmo Pharmaceuticals N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.